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ABSTRACT 
 
The effects of Jerusalem artichoke and fermented soybean powder 
mixture supplementation on blood glucose and oxidative stress in 
subjects with prediabetes or newly diagnosed type 2 diabetes 
 
 
Cho Rong Seo 
Department of Science for Aging 
The Graduate School 
Yonsei University 
 
Objective: The objective was to evaluate the effect of jerusalem artichoke 
and fermented soybean powder mixture supplementation on blood glucose 
and oxidative stress. 
 
Methods: A randomized, double-blinded, placebo-controlled study was 
conducted on 60 subjects with impaired fasting glucose (IFG), impaired 
glucose tolerance (IGT) or newly diagnosed type 2 diabetes (T2DM). The 
subjects were randomly assigned to either a group ingesting 40 g jerusalem 
vii 
 
artichoke and fermented soybean powder mixture supplementation daily or 
a placebo group for 12-week. We assessed fasting and postprandial levels of 
glucose, free fatty acid (FFA), homeostasis model assessment-insulin 
resistance (HOMA-IR), and oxidative stress markers. 
 
Results: The jerusalem artichoke and fermented soybean powder mixture 
supplementation reduced fasting glucose (p=0.001) and FFA (p=0.008), 
glucose level at 60 min (p=0.004), and glucose (p=0.007) and FFA (p=0.044) 
areas under the response curve (AUC), and HOMA-IR (p=0.032). The 
jerusalem artichoke and fermented soybean powder mixture 
supplementation also decreased urinary 8-epi-prostaglandin F2α (8-epi-
PGF2α) (p=0.028). In addition, △ glucose at 120 min (r=0.472, p=0.027) and 
△ glucose AUC (r=0.572, p=0.005) correlated positively with △ plasma 
malondialdehyde (MDA) in the test group. 
 
Conclusion: The consumption of jerusalem artichoke and fermented 
soybean powder mixture supplementation for 12 weeks reduced fasting and 
postprandial glucose and oxidative stress in subjects with IFG, IGT or newly 
diagnosed T2DM.
viii 
 
 
 
KEY WORDS: jerusalem artichoke; fermented soybean; prediabetes;     
newly diagnosed type 2 diabetes; glucose; oxidative stress 
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1. INTRODUCTION 
Diabetes is common chronic metabolic disease worldwide that 
results from the reduced function of organs, such as lack of insulin or insulin 
resistance [1]. According to the World Health Organization (WHO), 347 
million people worldwide had diabetes in 2013 and diabetes will be the 7th 
cause of death by 2030 [2]. In 2010, the prevalence of diabetes worldwide 
was 6.4 % and will increase to 7.7 % by 2030 [3]. According to the ‘2013 
Korean National Health and Nutrition Examination Survey’, the incidence 
of diabetes increased 2 % since 2012 [4]. IFG, IGT or both are at high risk 
of progressing to T2DM that are risk for cardiovascular disease [5,6]. The 
progression of IFG or IGT to T2DM can be delayed or prevented by 
lifestyle change and pharmacological interventions [7]. According to the 
American Diabetes Association, medical nutrition therapy is an effective 
therapy in the management of diabetes [8]. 
Jerusalem artichoke is a root vegetable that the main component is 
fructans (fructose molecules connected by β-2,1 bonds), which are inulin 
and fructooligosaccharides [9]. Inulin and fructooligosaccharides have been 
reported to stimulate immune system, reduce the synthesis of triglycerides 
and fatty acids in the liver, and decrease the blood glucose levels [10].    
Fermented soybean has been reported the antidiabetic effects in diabetic 
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animals and humans [11-13]. The previous study reported that combination 
of jerusalem artichoke and fermented soybean had complementary 
antidiabetic effects through potentiation of insulinotropic action and 
reduction of insulin resistance in diabetes rat [14]. Therefore, we 
hypothesized that this might be extrapolated to the human and the aim of 
this study was to investigate the effect of jerusalem artichoke and fermented 
soybean powder mixture supplementation on blood glucose and oxidative 
stress. 
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2. BACKGROUND 
2.1. Diabetes Mellitus diagnosis 
The diagnosis of diabetes mellitus is based on plasma glucose criteria, 
both the Hemoglobin A1c (HbA1c) test and the fasting plasma glucose 
(FPG) or the oral glucose tolerance test (OGTT) (Table 1) [15]. 
 
Table 1. Criteria for the diagnosis diabetes 
HbA1c ≥ 6.5  % ＊ 
OR 
FPG ≥ 126 mg/dL (7.0 mmol/L)＊ 
OR 
2-h plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT＊ 
OR 
In a patient with classic symptom of hyperglycemic or hyperglycemic crisis, 
a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) 
＊In the absence of unequivocal hyperglycemia, result should be confirmed by repeat 
testing [15].
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Normal blood glucose levels is defined when postprandial blood      
glucose concentration is under the 140 mg/dl or fasting blood glucose  
concentration is 70-100 mg/dl [15]. 
Both IGT and IFG are not diabetes mellitus correctly, but they are 
considered as ‘prediabetes’. So they mean blood glucose levels are higher 
than nomal and, a high potential of progress to diabetes (Table 2) [16]. 
Impaired glucose regulation is related to a high rate of cardiovascular 
disease (CVD) and CVD motality [17-18]. 
 
Table 2. Categories of increased risk for diabetes (prediabetes)  
 
IGT 
2-h plasma glucose in the 75 g OGTT 14 
mg/dL (7.8 mmol/L) to 199 mg/dL(11.0  
mmol/L) 
OR 
 
IFG 
FPG ≥100 mg/dL (5.6 mmol/L) to 125 mg/dL 
(6.9 mmol/L) 
OR 
 
HbA1c ≥ 6.5 %  
 
5.7 – 6.4  % ＊ 
＊For all there tests, risk is continuous, extending below the lower limit of the range and 
becoming disproportionately greater at higher ends of the range [15].
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2.2. Helianthus tuberosus L. 
2.2.1. The characteristics of Helianthus tuberosus L. 
Helianthus tuberosus L., also known as ‘Jerusalem artichoke’, is a 
perennial plant that originated in North America, but grows throughout 
Korea due to suitable climatic conditions. 
The main component of Helianthus tuberosus L. is inulin, a fructose 
polymer (fructose molecules connected by β-2,1 bonds) [19] that accounts 
for 75 %  of the Helianthus tuberosus L. dry weight [20]. Helianthus 
tuberosus L is a perennial grass 1~3 m tall, with an irregularly shaped 
rhizome. Its straight stem branches at the top, with short and tough hair or 
bristles. 
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2.2.2. The effects of Helianthus tuberosus L. 
Inulin is a dietary fiber common to a number of tuberous plants such 
as chicory, yacon, and dahlia in addition to Helianthus tuberosus L. It has 
been reported to relieve constipation, prevent intestinal diseases, and reduce 
serum cholesterol, serum lipid, and blood sugar levels [21]. Therefore, there 
is growing need to scientifically examine the functionality of Helianthus 
tuberosus L. using standardized inulin content to test its effects on blood 
sugar in appropriate human subjects. Based on previous clinical studies, the 
Ministry of Food and Drug Safety (MFDS) has approved inulin for ‘blood 
cholesterol improvement,’ ‘inhibition of blood sugar increase after meals,’ 
and ‘contribution to active bowel movement’ [22].  
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2.3. Fermented soybean paste 
2.3.1. Characteristics of fermented soybean paste  
Fermented soybean paste is a traditional fermented food that is 
ubiquitous in Korea’s dietary culture. It offers great nutritional value and is 
a valuable protein source in the standard grain-rich Korean diet. Along with 
other types of pastes, fermented soybean paste has been an important 
protein source for Koreans, who have traditionally had a relatively low 
protein intake. It is a highly nutritious food that is higher in protein and fat 
than bean or chili pastes [23]. 
 
Because Bacillus species are responsible for the fermentation, enzymes 
and various bioactive substances are found in fermented soybean paste that 
are not present in soybeans. Bacteria such as B. Subtilis or B. licheniformis 
weaken the activity of intestinal saprogenic bacteria, have antibacterial 
effects on pathogens, and even adsorb and excrete toxins [24].  
In addition, bioactive substances produced during the fermentation process 
have been reported to be effective in chronic degenerative diseases, 
increasing awareness of fermented soybean paste [25]. 
8 
 
2.3.2. The effects of fermented soybean paste  
Soybeans have long been known to have positive effects on diabetes in 
Korea, and several studies proved its effectiveness in decreasing blood sugar 
levels and blood lipid concentrations [26-28].  
Kwon et al. [29] reported suppression of the increase in post-meal 
blood sugar levels when diabetic animal models were provided short-term 
diets containing soybean or fermented soybean paste. This is likely because 
soybean or fermented soybean paste inhibits the activity of carbohydrate 
digestive enzyme (α-glucosidase) in the small intestine, and soluble dietary 
fiber from soybean or fermented soybean paste slows the movement of food 
in the digestive tract. 
Pinitol, a sugar alcohol of soybeans, is converted to chiro-inositol, 
which complements the insulin signal transduction system in tissues and 
lowers blood sugar, thereby exerting an anti-diabetic effect [30]. 
Other studies reported that supplementing mice with soybean powder 
or fermented soybean paste resulted in decreased blood sugar levels, as well 
as reduced glycosylated hemoglobin and serum lipid concentrations. 
Supplementing fermented soybean paste in particular, rather than soybean 
powder, reportedly had a superior effect on blood sugar control and 
improved lipid metabolism [31].
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Soybean intake suppresses obesity and improves insulin resistance, and may 
therefore contribute to diabetes prevention and treatment [32-33]. 
  
2.4. The beneficial effects of combined Jerusalem artichoke 
powder and fermented soybean paste 
Thus, a combination of Helianthus tuberosus L. powder and fermented 
soybean paste may have a synergetic effect on blood sugar control and 
blood control mechanisms due to increased insulin secretion and decreased 
insulin resistance induced by fermented soybean paste and Helianthus 
tuberosus L, respectively. A previous study reported that a 5 %  
combination of Helianthus tuberosus L. powder and fermented soybean 
paste [34] added to the diet of sprague-dawley (SD) rats significantly 
decreased blood sugar levels, increased insulin secretion, and decreased 
insulin resistance based on results of OGTT. 
Therefore, this study aimed to inulin, the major component of 
Helianthus tuberosus L., based on nonclinical studies, and to verify its 
effects on blood sugar control in humans with the expectation of synergetic 
effects on blood sugar control with added fermented soybean paste, in order 
to develop a functional food with high value. 
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3. SUBJECTS AND METHODS 
3.1. Study subjects 
Participants were included in age between 20 and 70 year old and 
recruited from the outpatient clinics at Ilsan hospital (Gyeonggi-do, Korea) 
and advertisements in local newspaper. After the glucose screening test, 
subjects with IFG (100 mg/dL ≤ IFG ≤ 125 mg/dL) or IGT (140 mg/dL ≤ 
IGT ≤ 199 mg/dL 2-h OGTT) or newly diagnosed T2DM (fasting glucose ≥ 
126 mg, blood glucose ≥ 200 mg/dL 2-h OGTT) were enrolled in the study. 
 
Exclusion criteria that all selected patients met were: 
- Having insulin injections or taking glucose-lowering medications 
- Having an evidence or alcoholism 
- Pregnant of in breast feeding 
- Having chronic gastrointestinal disorders 
- Patients with serious kidney problems 
- Patients with serious liver problems 
- Other patients who were considered unsuitable for this study by 
the researchers 
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60 study subjects with IFG or IGT were enrolled and they gave written 
consent forms for the study, which protocol was approved by the 
Institutional Review Board of Yonsei University. 
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3.2. Study design and test product  
 
This study was a randomized, double-blind, placebo-controlled 
intervention trial, lasting a total of 12 weeks. The study subjects were 
assigned randomly to either test group (n=30) or placebo group (n=30) and 
study design is presented below (Figure 1). 
 
 
 
 
 
 
 
 
 
 
Participants were randomly assigned to the test group or the placebo 
group. 8 people gave up the middle among the study participant total 60 
peoples due to the personal private. The compliance of the test product 5 
people was dropped because of 80 %  less than over the study period. The 
Screening 
Test group (40 g/day, n=30) 
Placebo group (40 g/day, n=30) 
Randomization End of Study 
n=60 
Screening visit 
- 2 week 
Run-in-Period 
0 week 6 week 12 week 
Figure 1. Study design 
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test group (n=22) consumed a combination of Helianthus tuberosus L. 
powder and fermented soybean paste before each meal (3 times/day for 12 
weeks). And the placebo group (n=25) consumed powdered rice flour before 
each meal (3 times/day for 12 weeks). The products were provided by 
Midari Farm (Yeongwol, Kangwon-Do, Korea). Composition of test 
product and placebo product is shown in Table 3. 
 
Table 3. Composition of test product and placebo product 
Test product 
 Component Content ( % ) 
Main component A combination of Helianthus tuberosus L. 
powder and fermented soybean paste 
97.27 
Excipien Cornstarch 2.65 
Caramel Color 0.07 
L-mentol 0.01 
total  100 
Placebo product 
 Component Content ( % ) 
Excipien Rice flour 84.71 
Cornstarch 2.32 
Caramel Color 0.003 
L-mentol 0.01 
Water 12.96 
total  100 
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Participants met with the investigational team at four different time 
points : screening (Week 2), randomization and treatment baseline (Week 0), 
treatment midpoint (Week 6), and treatment endpoint (Week 12). Daily 
intake were measured 24-hour recall method and physical activity at week 0, 
week 6, and week 12 of the treatment period. Compliance with study 
restrictions and products consumption was monitored via daily document by 
participants on individualized study calendars and end-study count of 
returned products. 
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3.3. Materials and methods 
3.3.1 Dietary food intake and total energy expenditure 
Usual food intake assessed using a 24-hour recall method and a 
semiquantitative food frequency quency questionnaire (FFQ) [35]. 
Total nutrient intake was examined and calculated based on the 3-day 
dietary records using the Computer Aided Nutritional Analysis Program 
(CAN-pro 3.0, Korean Nutrition Society, Seoul, Korea). 
Total energy expenditure (TEE, kcal/day) was calculated based on basal 
metabolic rate (BMR), the activity patterns of participants, 24-hour physical 
activity [36], and the food specific dynamic action. The BMR for each 
subject was calculated with the Harris-Benedict equation [37].  
 
3.3.2. Anthropometric parameters, blood pressure, and 
blood and urine collection 
Height and weight were measured in the morning and Body Mass 
Index (BMI) was by the standard formula (kg/m
2
). Waist and hip 
circumferences were measured using a flexible measuring tape and used to 
calculate the waist to hip ratio (WHR). Blood pressure (BP) was measured 
in the left arm with an automatic BP monitor (EASY X 800, Jawon Medical, 
16 
 
Republic of Korea). After a 12-hour fast period, venous blood specimens 
were collected in ethylenediaminetetraacetate (EDTA) treated tubes and 
plain tubes that were centrifuged to produce plasma and serum. Urine was 
collected in polyethylene bottles containing 1 %  butylated hydroxytoluene. 
The collected samples were stored at -70 °C until analysis. 
 
3.3.3. Serum lipid profiles 
TG and Total serum cholesterol (T-chol) were measured using  
available kits on Hitachi model 7600 autoanalyzer (Hitachi Ltd., Tokyo, 
Japan). High density lipoprotein cholesterol (HDL-C) in the supernatant was 
measured by an enzymatic method. Low density lipoprotein cholesterol 
(LDL-C) was indirectly estimated for subjects using the Friedewald 
Formula with serum TG levels<400 mg/dL (4.52 mol/L) [Friedewald 
formula ; LDL-chol = T-chol – {HDL-chol – (TG × 0.2)}].  
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3.3.4. Blood glucose level, related biomarkers, and  
free fatty acids (FFA) 
Serum glucose was measured using a hexokinase method with a 
Hitachi 7600 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). Serum insulin was 
measured by an immunoradiometric assay kit from DIA source 
ImmunoAssays S.A. (Louvain, Belgium). IR was calculated by the HOMA 
using the following equation: HOMA-IR=[Fasting insulin (μIU/mL) × 
Fasting glucose (mmol/L)] / 22.5. Serum C-peptide was measured by an 
immunoradiometric (IRMA) assay with a C-peptide IRMA kit (Immunotech, 
Czech). HbA1c was measured by an Immunoturbidimetric analyzer with a 
turbidimeter. FFA were measured by an enzymatic assay using the acylCoA 
synthetase-acylCoA oxidase (ACS-ACOD) method with a Hitachi 7600 
Autoanalyzer (Hitachi Ltd., Tokyo, Japan). 
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3.3.5. Urinary 8-epi-prostaglandin F2α (8-epi-PGF2α) and 
plasma malondialdehyde (MDA) 
Urinary 8-epi-PGF2a was measured by a urinary isoprostane ELISA kit 
(Oxford Biomedical Research Inc., Rochester Hills, MI). Urinary creatinine 
levels were determined using an alkaline picrate (Jaffe) reaction. Plasma 
MDA was measured using thiobarbituric acid-reactive substances (TBARS) 
by a TBARS Assay Kit (ZeptoMetrix Co., Buffalo, NY). 
 
3.3.6. Statistical analysis 
Statistical analysis was performed with SPSS version 21.0 (IBM/SPSS 
Corp. Chicago, IL, USA). A paired t-test with the Wilcoxon signed rank test 
was evaluated to compare the effect within each group both before and after 
intervention. An independent t-test with the Mann-Whitney U-test was 
evaluated to compare net change between the test and placebo groups. The 
logarithmic transformation was performed on skewed variables. The results 
were expressed as mean ± SE and a p-value < 0.05 was considered 
statistically significant. 
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4. RESULTS 
4.1. The clinical and biochemical characteristics at baseline 
The clinical and biochemical characteristics of the placebo and test 
groups were showed in Table 4. There was no significant difference between 
the groups in baseline characteristics (i.e. age, sex distribution, height, 
weight, BMI, WHR, BP, serum lipid profiles, HbA1c, glucose, insulin, 
HOMA-IR, C-peptide, FFA, or MDA). Urinary 8-epi-PGF2α was 
significantly different between two groups at baseline (p=0.032). Estimated 
total calorie intake (TCI), TEE, BMR, % carbohydrate intake, % protein 
intake, and % fat intake did not significantly differ between groups (data not 
shown). 
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Table 4. Clinical and biochemical characteristics of placebo and test groups at baseline 
 
Total (n=47) 
P 
Placebo group (n=25) Test group (n=22) 
Age (year)  56.0 ±1.28   54.4 ±1.31  0.390 
Male/Female n, ( % )  10 (40.0) / 15 (60.0)   4 (18.2) / 18 (81.8)  0.102 
Height (cm)  161.6 ±1.24   158.9 ±1.38  0.154 
Weight (kg)  64.3 ±1.72   60.4 ±2.35  0.188 
BMI (kg/m
2
)  24.6 ±0.50   23.8 ±0.63  0.336 
WHR  0.90 ±0.01   0.88 ±0.01  0.387 
Systolic BP (mmHg)  128.5 ±2.69   127.4 ±3.17  0.801 
Diastolic BP (mmHg)  79.5 ±1.72   82.2 ±1.83  0.291 
Total-chol (mg/dL)
∮
  193.7 ±5.29   201.6 ±6.03  0.320 
HDL-chol (mg/dL)
∮
  51.6 ±1.91   58.0 ±2.77  0.076 
LDL-chol (mg/dL)
∮
  119.9 ±4.90   120.9 ±6.38  0.993 
TG (mg/dL)
∮
  110.9 ±10.1   114.0 ±13.1  0.976 
HbA1c ( % )
∮
  5.96 ±0.07   5.99 ±0.14  0.909 
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Table 4. (continued) 
Mean ± SE. 
∮
Tested by logarithmic transformation, P-values derived from independent t-test with the Mann-Whitney U-test. 
HOMA-IR: {fasting insulin (μIU/mL) × fasting glucose (mmol/L)}/22.5, 8-epi-PGF2α: urinary 8-epi-prostaglandin F2α. 
 
Total (n=47) 
P 
Placebo group (n=25) Test group (n=22) 
Glucose (mg/dL)
∮
  107.6 ±1.48   107.2 ±1.68  0.839 
Insulin (μIU/dL)
∮
  9.92 ±0.55   10.1 ±0.84  0.969 
HOMA-IR  2.66 ±0.17   2.71 ±0.25  0.937 
C-peptide (μEq/L)
∮
  2.16 ±0.12   2.21 ±0.16  0.977 
Free fatty acid (μEq/L)
∮
  572.4 ±42.0   663.2 ±50.5  0.132 
8-epi-PGF2α (pg/mg creatinine)
∮
  1699.4 ±141.0   2427.7 ±284.6  0.032 
Malondialdehyde (nmol/mL)
∮
  8.68 ±0.35   8.33 ±0.27  0.685 
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4.2. The effects of a 12-week consumption of jerusalem 
artichoke and fermented soybean powder mixture 
supplementation on blood glucose level 
 
Except for blood glucose level, HOMA-IR, FFA, and urinary 8-epi-
PGF2α, there were no significant mean changes in any of the tested clinical 
and biochemical characteristics between the placebo and test groups (data 
not shown). After 12 weeks of treatment, the test group showed a significant 
decrease in serum level of blood glucose at 0 min (p=0.001), 60 min 
(p=0.004), and glucose AUC (p=0.007) (Table 5). The change in serum level 
of blood glucose at 60 min (p=0.013), 120 min (p=0.021), and glucose AUC 
(p=0.012) in test group was significantly different from the placebo group. 
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Table 5. Blood glucose level and glucose related biomarkers of study participants 
 
Total (n=47) 
P
a
 P
b
 P
c
 P
d
 Placebo group (n=25) Test group (n=22) 
Baseline Follow-up Baseline Follow-up 
Glucose 0 min (mg/dL)
∮
 107.6 ±1.48 101.3 ±1.73
**
 107.2 ±1.68 97.7 ±2.63
***
 0.839 0.193   
Change  -6.28 ±1.78   -9.45 ±1.90    0.230 0.210 
Glucose 30 min (mg/dL)
∮
 189.2 ±6.36 185.6 ±6.56 189.7 ±9.73 186.8 ±8.17 0.849 0.956   
Change  -3.56 ±4.84   -2.91 ±8.86    0.947 0.963 
Glucose 60 min (mg/dL)
∮
 192.3 ±9.88 195.8 ±9.51 205.2 ±11.8 181.3 ±12.0
**
 0.402 0.243   
Change  3.56 ±7.28   -23.9 ±7.74    0.013 0.021 
Glucose 120 min (mg/dL)
∮
 153.4 ±8.71 166.5 ±11.5 167.7 ±11.2 154.0 ±11.8 0.367 0.463   
Change  13.1 ±8.22   -13.7 ±7.51    0.021 0.031 
Glucose AUC (mg/dLh)
∮
 342.4 ±13.1 348.3 ±14.5 359.4 ±17.3 330.8 ±16.3
**
 0.470 0.378   
Change  5.86 ±9.05   -28.6 ±9.45    0.012 0.017 
Free fatty acid 0 min (μEq/L)
∮
 572.4 ±42.0 647.6 ±43.6 663.2 ±50.5 563.7 ±26.2
*
 0.132 0.175   
Change  75.2 ±45.9   -99.5 ±41.6    0.008 0.027 
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Table 5. (continued) 
Mean ± SE. ∮tested by logarithmic transformation, P
a
-values derived from independent t-test in baseline with the Mann-
Whitney U-test. P
b
-values derived from independent t-test in follow-up with the Mann-Whitney U-test. P
c
-values derived 
from independent t-test with the Mann-Whitney U-test in Changed value. P
d
-values adjusting for baseline. 
*
P <0.05, 
**
P 
<0.01, 
***
P <0.001 derived from paired t-test with the Wilcoxon signed rank test. AUC: area under the curve. 
 
Total (n=47) 
P
a
 P
b
 P
c
 P
d
 Placebo group (n=25) Test group (n=22) 
Baseline Follow-up Baseline Follow-up 
Free fatty acid 30 min (μEq/L)
∮
 304.6 ±23.5 350.2 ±30.3 334.8 ±41.4 327.1 ±32.6 0.986 0.652   
Change  45.6 ±23.6   -7.77 ±38.8    0.234 0.163 
Free fatty acid 60 min (μEq/L)
∮
 251.2 ±27.5 281.8 ±30.6 251.6 ±33.3 254.5 ±40.3 0.935 0.268   
Change  30.6 ±20.8   2.86 ±27.7    0.421 0.400 
Free fatty acid 120 min(μEq/L)
∮
 92.4 ±4.40 84.5 ±5.48 104.2 ±13.9 88.1 ±9.80 0.961 0.794   
Change  -7.92 ±5.18   -16.1 ±13.2    0.569 0.429 
Free fatty acid AUC (μEq/Lh)
∮
 530.0 ±29.2 590.6 ±30.4 574.0 ±39.2 539.3 ±34.5 0.401 0.237   
Change  60.6 ±33.5   -34.7 ±30.8    0.044 0.066 
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4.3. The effects of a 12-week consumption of jerusalem 
artichoke and fermented soybean powder mixture 
supplementation on blood glucose related biomarkers 
 
The 12 weeks intervention with jerusalem artichoke and fermented 
soybean powder mixture supplementation resulted a significant reduction in 
HOMA-IR (p=0.032) (Figure 2). Serum FFA level at 0 min in the test group 
showed a significant decrease after 12-week intervention (p=0.034) (Table 
5). The change in serum level of FFA at 0 min (p=0.008), and FFA AUC 
(p=0.044) in test group was significantly different from the placebo group. 
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Figure 2. HOMA-IR at initial visit (□) and at 12-week follow-up (■) and  
mean changes according to treatment 
Mean ± SE. 
§
Tested by logarithmic transformation. P-values determined using an 
independent t-test with the Mann-Whitney U-test. 
*
P<0.05 compared with baseline 
values in each group as determined by paired t-test with the Wilcoxon signed rank 
test.
0
0.5
1
1.5
2
2.5
3
3.5
HOMA-IR
§
 
       Placebo                Test 
-0.6
-0.4
-0.2
0
HOMA-IR 
change 
 Placebo               Test 
 
P=0.716 
HOMA-IR 
* 
27 
 
4.4. The effects of a 12-week consumption of jerusalem 
artichoke and fermented soybean powder mixture 
supplementation on oxidative stress markers 
 
After 12 weeks of treatment, the test group showed a significant decrease 
in urinary 8-epi-PGF2α (p=0.028) and the placebo group showed a 
significant increase in urinary 8-epi-PGF2α (p=0.040) (Figure 3). The change 
in urinary 8-epi-PGF2α in test group was significantly different from the 
placebo group (p=0.003). In the test group, △ glucose 120 min was 
positively correlated with △ MDA (r=0.472, p=0.027), and △ glucose AUC 
was positively correlated with △ MDA (r=0.572, p =0.005) (Figure 4). 
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Figure 3. Urinary 8-epi-PGF2α levels at initial visit (□) and at 12-week 
follow-up (■) and mean changes according to treatment. 
Mean ± SE. 
§
Tested by logarithmic transformation. P-values determined using an 
independent t-test with the Mann-Whitney U-test. 
*
P<0.05 compared with baseline 
values in each group as determined by paired t-test with the Wilcoxon signed rank 
test.
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Figure 4. Correlation between changes (difference from baseline) in blood glucose level and plasma MDA  
in the placebo and test groups. 
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r : Spearman’s correlation coefficients. 
Figure 4. (continued) 
Δ
 M
D
A
 
Δ
 M
D
A
 
Δ
 M
D
A
 
Δ glucose AUC Δ glucose AUC 
31 
 
5. DISCUSSION 
The antidiabetic effects of jerusalem artichoke and fermented soybean 
have raised interest in recent years. The antidiabetic mechanisms of 
jerusalem artichoke and fermented soybean might be different. Therefore, 
we hypothesized that the combination of the jerusalem artichoke and 
fermented soybean might have a synergy. This randomized, double-blind, 
placebo-controlled study evaluated the effect of jerusalem artichoke and 
fermented soybean powder mixture supplementation on glucose control in 
subjects with IFG, IGT, or newly T2DM. The 12 weeks intervention with 
jerusalem artichoke and fermented soybean powder mixture 
supplementation resulted in an improvement in blood glucose and glucose 
related biomarkers as well as a reduction in oxidative stress. 
Main component of jerusalem artichoke is fructans, which were inulin 
and fructooligosaccharides that were not absorbed in the intestines [38]. 
Therefore, consumption of jerusalem artichoke did not affect insulin levels 
and the present study showed that jerusalem artichoke and fermented 
soybean powder mixture supplementation had not effect on insulin levels. 
The previous study showed that fructooligosaccharides supplementation 
reduced the fasting plasma glucose levels after 2 weeks in T2DM [39]. 
Other clinical trial demonstrated antidiabetic effect of inulin-enriched pasta 
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in human, which reduced fasting glucose levels, HbA1c and HOMA-IR [40]. 
The in vivo studies reported that jerusalem artichoke supplementation 
improved IR and decreased the OGTT [41] and plasma glucose level 
decreased with increasing level of supplemented jerusalem artichoke [42]. 
Inulin and fructooligosaccharides might affect glucose levels by changing 
the secretion of glucagon-like peptide-1 (GLP-1), which increased insulin 
secretion, delayed gastric emptying, promoted β-cell proliferation, and 
reduced β-cell apoptosis [43-47]. The mechanisms of hypoglycemic effect 
by jerusalem artichoke remains largely obscure. 
In clinical trial, fermented soybean product consumption decreased 
fasting blood glucose and HbA1c after 3 months in borderline and mild 
T2DM subjects [48]. The previous studies showed that long-term 
consumption of fermented soybean attenuated IR and improved glucose 
homeostasis in type 2 diabetic animal model [11,49]. The biologically active 
components of fermented soybean were isoflavonoids and small peptides 
that are associated with insulin resistance and glycemic control [50,51]. The 
potential mechanisms could be explained the antidiabetic effect of 
fermented soybean. According to the previous study, isoflavonoids might 
have antidiabetic effect through estrogen-like action. Estrogen might reduce 
insulin resistance through inhibition of intestinal glucose uptake and 
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prevention of glucose-induced lipid peroxidation by decreasing sodium-
dependent glucose transporter [52]. In addition, estrogen might be 
associated with the stimulation of liver fatty acid metabolism and 
suppression of hepatic glucose production [53]. FFA was known to cause 
insulin resistance by inhibiting insulin-stimulated glucose uptake. High level 
of plasma FFA was associated with to increase diacylglycerol and to activate 
protein kinase C, which leading to increased tyrosine phosphorylation of the 
insulin receptor substrate-1 and resulting in increased insulin-stimulated 
glucose transport activity and IR [54,55]. The present study showed that 
jerusalem artichoke and fermented soybean powder mixture 
supplementation decreased FFA and IR that might be explained by 
isoflavonoids of fermented soybean. 
T2DM was associated with oxidative stress and lipid peroxidation was 
the main marker of oxidative stress that played the major role in the 
pathogenesis of T2DM [56]. 8-epi-PGF2α was secondary end products of 
peroxidation that could impair β-cell function and lead to apoptosis [57]. 
Improved metabolic control reduced 8-epi-PGF2α by 32 %  in T2DM 
patients [58] and the clinical trial reported that 8-epi-PGF2α was threefold 
higher in T2DM patients than in healthy individuals [59]. Therefore, level of 
8-epi-PGF2α presented the diabetic state.  
34 
 
In present study, we observed that 8-epi-PGF2α significantly decreased 
in the test group. Jerusalem artichoke and fermented soybean powder 
mixture supplementation had an effect on reduction of oxidative stress in 
subjects with IFG, IGT, or newly diagnosed T2DM. MDA was a primary 
biomarker of free radical mediated lipid damage and oxidative stress that 
was elevated in T2DM patients [60-62]. The previous finding could explain 
the positive correlation between changes in glucose with changes in MDA in 
the test group of this study that presented lipid peroxidation was related to 
glycemic control and affected by jerusalem artichoke and fermented 
soybean powder mixture supplementation. The result of present study was 
concluded that inulin of jerusalem artichoke and isoflavonoids of fermented 
soybean might affect complementary glucose control and jerusalem 
artichoke and fermented soybean powder mixture supplementation was able 
to improve the already existing oxidative stress in subjects with IFG, IGT, or 
newly diagnosed T2DM. 
There are several limitations in our study design. First, we specifically 
focused on Korean subjects with IFG, IGT, or newly diagnosed T2DM. 
Therefore, our data cannot be generalized to other ethnic groups or severe 
T2DM patients. Second, because of the small sample size, the results should 
be interpreted with caution. Despite these limitations, 
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jerusalem artichoke and fermented soybean powder mixture 
supplementation for 12 weeks showed antidiabetic and antioxidant effects in 
IFG, IGT, or newly diagnosed T2DM subjects. 
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국문 요약 
 
 
당뇨 전 단계 또는 초기 제 2형 당뇨병 환자의 
 혈당 및 산화스트레스에 대한 돼지감자 청국장 
분말 섭취의 효과 
 
당뇨병은 만성대사성 질환으로 전 세계적으로 유병률이 증가하
고 있으며, 당뇨 전 단계인 공복혈당장애와 내당능장애는 당뇨병 
뿐만 아니라 심혈관계 질환을 유발할 수 있는 위험인자로 대두되
고 있다. 당뇨와 심혈관계 질환을 예방하고 삶의 질을 높이기 위
해서는 효과적인 혈당의 조절이 중요하다고 할 수 있다. 
돼지감자 (Helianthus tuberosus L.)는 국화과 해바라기속의 다년생 
식물로 주 성분은 Fructose 중합체 (Fructose 분자들이 β-2,1 결합
으로 연결)인 Inulin이며 식품의약품안전처는 현재까지 수행된 인
체적용시험 중심으로 Inulin의‘혈중 콜레스테롤 개선’,‘식후 혈
당상승 억제’,‘배변활동 원활에 도움을 줄 수 있음’의 기능성
을 인정하고 있다. 
청국장은 예로부터 우리나라의 식생활에서 빠질 수 없는 대두를 
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발효한 전통발효식품으로 단백질 섭취량이 비교적 적은 한국인에
게 장류와 함께 단백질의 중요한 공급원이었다. 콩의 섭취가 비만
을 억제하고, 인슐린 저항성을 개선시켜 당뇨병의 예방 및 치료에 
도움을 주는 것으로 여러 연구에서 콩의 혈당 및 혈중 지질농도 
저하효과가 입증되었다. 
따라서, 본 연구에서는 규명된 작용기전을 통해 돼지감자와 청
국장의 시너지 효과를 기대하며 사람을 대상으로 혈당조절 기능성
을 검증함으로서 고부가가치의 건강기능식품을 개발하는 것을 목
표로 연구를 진행시키고자 하였다. 
본 연구에서는 무작위 배정, 이중맹검, 플라시보 대조 디자인의 
인체적용시험을 통하여 공복혈당장애 및 내당능장애 및 초기당뇨
를 가진 대상자에게서 돼지감자 청국장 분말의 섭취가 혈당조절과 
산화스트레스에 미치는 영향을 평가하였다. 
 공복혈당장애, 내당능장애, 초기 당뇨병 환자 60명을 대상으로 
돼지감자 청국장 분말 또는 플라시보를 12주간 섭취하도록 한 후, 
혈당, 혈당반응면적, 인슐린, C-peptide, FFA, 8-epi-PGF2α, MDA 등
을 측정하여 섭취 전후의 유의적 변화가 있는지 확인하고, 대조군
과 실험군 간의 유의적 차이가 있는지 검정하였다. 
 그 결과 실험군은 혈청에서의 공복혈당 (p=0.001)과 유리지방산
(p=0.008)이 유의적으로 감소하였고, 혈청에서 분석한 60분째 혈
당이 205.2±11.8 mg/dL에서 12주 후 181.3±12.0 mg/dL (p=0.004)
로 크게 감소하였다.  
혈당관련 바이오마커인 혈당반응면적 (p=0.007)과 인슐린저항성
(p=0.032), 0분에서 혈청의 유리지방산 (p=0.034) 또한 유의적으
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로 감소하였다. 또한 산화스트레스 지표인 8-epi-PGF2는 12주 후 
실험군 (p=0.003)과는 다르게 대조군 (p=0.040)은 증가하였고, 실
험군에서 혈당수치과 혈장 MDA에서 베이스라인과 다르게 상관관
계를 보였다. 
결론적으로 본 연구에서는 당뇨병 전 단계인 공복혈당장애와 내
당능장애, 초기 당뇨병 대상자들에게 12주 간 식사 전 1일 3회 
(40 g) 의 돼지감자 청국장 분말을 섭취시켰을 때 공복혈당 및 식
후혈당과 산화스트레스 관련 지표가 개선되는 것을 볼 수 있었다. 
앞으로의 연구에서 좀 더 정확한 결과를 얻기 위해서는 대상자 
수를 더 확보하고 용량을 세분화한 후속 연구가 필요할 것으로 사
료된다.  
 
 
 
 
 
 
 
 
 
 
 
핵심 용어 : 당뇨 전 단계; 초기 제 2형 당뇨; 돼지감자; 청국장; 
혈당; 산화스트레스 
 
